about
Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer.Identification of eusynstyelamide B as a potent cell cycle inhibitor following the generation and screening of an ascidian-derived extract library using a real time cell analyzer.Reduced Expression of TET1, TET2, TET3 and TDG mRNAs Are Associated with Poor Prognosis of Patients with Early Breast CancerImpact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World PopulationHigh Levels of Nucleolar Spindle-Associated Protein and Reduced Levels of BRCA1 Expression Predict Poor Prognosis in Triple-Negative Breast Cancer.Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer.Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer.Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastasesSystemic Therapy for Early-Stage Breast Cancer: What the Plastic Surgeon Should Know.Synthesis and Biological Evaluation of Amidinourea and Triazine Congeners as Inhibitors of MDA-MB-231 Human Breast Cancer Cell Proliferation.Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation.microRNA-497 inhibits invasion and metastasis of colorectal cancer cells by targeting vascular endothelial growth factor-A.Synergistic antiproliferative effects of methotrexate-loaded smart silica nanocomposites in MDA-MB-231 breast cancer cells.MicroRNA-497 and bufalin act synergistically to inhibit colorectal cancer metastasis.7-ketocholesterol and 27-hydroxycholesterol decreased doxorubicin sensitivity in breast cancer cells: estrogenic activity and mTOR pathway.Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer.Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells.A microfluidic platform for drug screening in a 3D cancer microenvironment.Alterations in serum levels of trace element in patients with breast cancer before and after chemotherapy.Transcription factor ATF3 mediates the radioresistance of breast cancer
P2860
Q33898605-8EBD98D0-E513-4BB6-B266-79B7D372DD6EQ34411545-A3FBA0E4-6502-4F85-9C7D-31643A4144AAQ35710389-78108BAA-B417-40A9-9334-CA45F3BF93D7Q35716564-21FAED2F-61F0-4EBF-9292-8B2F3815F8C4Q35815004-D96E002B-8433-4625-805E-70C345C92B6EQ36550926-08DD171E-5F66-402E-B9D8-E51E117D0A90Q37130479-3FB62ADC-BD79-43C9-A087-90BC77F4B50DQ37163756-7B8315C0-4C11-4B5D-88D6-76F7ECF018ABQ37671187-0D840B2C-CA40-4D33-9213-17E13A5A60E5Q38721894-206504C9-0D5D-4657-BDCF-7B47AEE20412Q38783426-1FAC7773-B2D1-4ADE-8E53-E7387DF12902Q38796985-C1C12620-6020-4B81-BC20-6665DB3C2592Q38939701-F34455FF-09E5-4101-9E77-98129B0A37D5Q39038746-2A02873D-D16B-45B8-ADAF-78403EB980C3Q42371604-290B9905-C862-4C39-B2F2-E584CC2DCA83Q47109270-F823F883-91DA-4A0B-85E4-FB90251E4755Q48204107-446DF392-1BB7-494D-BAFE-D3215CDF0A2BQ50753792-0562544C-2F0D-4123-95B6-168B3B16CFBAQ54943173-27522244-75B7-4E3F-A677-F7AC6D0F3F5BQ58767608-67F88DFA-5BB6-4A53-BCB5-6520E93310B4
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Chemotherapy for breast cancer (Review).
@en
Chemotherapy for breast cancer
@nl
type
label
Chemotherapy for breast cancer (Review).
@en
Chemotherapy for breast cancer
@nl
prefLabel
Chemotherapy for breast cancer (Review).
@en
Chemotherapy for breast cancer
@nl
P2093
P356
P1433
P1476
Chemotherapy for breast cancer (Review).
@en
P2093
P304
P356
10.3892/OR_00000963
P577
2010-11-01T00:00:00Z